Results 121 to 130 of about 87,437 (368)
Innovative Agents for Actinic Keratosis and Nanocarriers Enhancing Skin Penetration [PDF]
, 2010 Actinic keratosis and cutaneous squamous cell carcinoma are of increasing importance with aging and increased ultraviolet light exposure in Western societies. Efficient and well-tolerated therapy is still a matter of concern.
Höltje, H.-D. +3 more
core +1 more source
The Journal of Pathology, EarlyView.Abstract Terminal deoxynucleotidyl transferase (TdT) is occasionally expressed in large B‐cell lymphoma (LBCL), and this causes difficulty in differential diagnosis from B‐lymphoblastic leukaemia/lymphoma (B‐ALL/LBL). We reviewed 31 cases of TdT‐positive LBCL and B‐ALL/LBL, and their final diagnosis included 19 diffuse large/high‐grade BCLs with MYC ...
Maria‐Myrsini Tzioni +27 more
wiley +1 more source
Rational design of a new cytarabine-based prodrug for highly efficient oral delivery of cytarabine
RSC Advances, 2018 To overcome the drawbacks of cytarabine such as bad liposolubility and low bioavailability, we rationally designed a new cytarabine-based prodrug for oral cytarabine delivery, realizing significantly enhanced bioavailability for cancer therapy.
Jing Zhang +5 more
openaire +3 more sources
Imaging of Abdominal Complications in Children With Acute Lymphoblastic Leukaemia
Journal of Medical Imaging and Radiation Oncology, EarlyView.ABSTRACT Acute lymphoblastic leukaemia (ALL) is the most common paediatric malignancy and remains one of the most common causes of cancer‐related death in children and adolescents. Five‐year overall survival rates now exceed 90% with current multidrug chemotherapeutic regimens. This improvement, coupled with the toxicity of chemotherapy, has led to the
Luke R. Holmes +2 more
wiley +1 more source
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy. [PDF]
, 2019 Introduction: Acute myeloid leukemia (AML) remains a disease with high mortality, especially for older patients and those with relapsed/refractory (R/R) disease.
Galkin, Maria, Jonas, Brian A
core +1 more source
Therapy reduction in patients with Down syndrome and myeloid leukemia: the international ML-DS 2006 trial [PDF]
, 2017 Children with myeloid leukemia associated with Down syndrome (ML-DS) have superior outcome compared with non-DS patients, but suffer from higher constitutional cytotoxic drug susceptibility.
Creutzig, U. +10 more
core +4 more sources
British Journal of Haematology, 2018 The current standard treatment of younger patients with mantle cell lymphoma (MCL) includes rituximab and highdose cytarabine (HD-AraC), usually followed by autologous stem cell transplantation (ASCT).
C. Visco +34 more
semanticscholar +1 more source
British Journal of Haematology, EarlyView.Proposed management of newly diagnosed Philadelphia chromosome‐positive (Ph+) acute lymphoblastic leukaemia (ALL) in transplant‐eligible patients. Suggested considerations when deciding the treatment pathway available to a newly diagnosed Ph+ ALL patient that would be deemed transplant eligible. Summary Acute lymphoblastic leukaemia (ALL) in 20%–30% of
Naranie Shanmuganathan, Andrew Grigg
wiley +1 more source
Recent Advances in Treatment of Primary Central Nervous System Lymphoma [PDF]
, 2014 Opinion statement Therapeutic options are limited in primary central nervous system lymphoma (PCNSL) with no uniform consensus on optimal management and few published, randomized trials.
Batchelor, Tracy T., Nayak, Lakshmi
core +1 more source
Delivery of cytarabine by pegylated liposomes for efficient, long-term anticancer effects [PDF]
, 2014 The cytosine arabinoside cytarabine is an effective marine-derived antineoplastic agent for the treatment of acute myelogrnous and lymphocytic leukemias.
Borges, C. +7 more
core